Sedation In ICU Setting Market Size, Share and Industry Analysis By Drug/Drug Class (Propofol, Benzodiazepams (Midazolam, etc.), Dexmedetomidine, Remifentanil), and Regional Forecast 2026-2034

The global sedation in ICU setting market size was valued at USD 3.47 billion in 2025. The market is projected to grow from USD 3.68 billion in 2026 to USD 4.83 billion by 2034, exhibiting a CAGR of 10.95% during the forecast period (2026-2034). Asia Pacific dominated the sedation in ICU setting market with a market share of 38.57% in 2025. 

According to statistics published by the United Nations, the global population aged 60 years and over is projected to increase from 962 million in 2007 to 2.1 Billion in 2050. This is expected to present a large patient pool suffering from comorbid illness, and subsequently lead to increasing ICU admission of elderly population worldwide.

Several longitudinal studies suggested that during the last two decades the number of elderly patients admitted to intensive care units have increased massively. For instance, a recent article published by a medical journal ‘Annals of Intensive Care’, suggested that in Europe, elderly patients comprise 10–20% of all ICU admissions.

As per the article published by the Journal of Hospital Administration, in Australia, the percentage of the elderly patients admitted to critical care units progressively increased from 8.6% in 2000 to 14.5% in 2015. This progressively increasing elderly patient pool presents a huge opportunity for market players in the ICU sedation market, to cater to the unmet needs, and market players should focus on new developments and innovations in the ICU sedation technique, to consolidate their market position.

Download Free sample to learn more about this report.

Global Sedation In ICU Setting Market Key Takeaways

Market Size & Forecast:

• 2025 Market Size: USD 3.47 billion
• 2026 Market Size: USD 3.68 billion
• 2034 Forecast Market Size: USD 4.83 billion
• CAGR: 10.95% from 2026–2034

Market Share:

• Asia Pacific dominated the sedation in ICU setting market with a 38.57% share in 2025, driven by rising ICU admissions due to an aging population with comorbid illnesses, expanding critical care infrastructure, and increased use of sedatives in mechanically ventilated patients.
• Propofol is projected to maintain dominance within the drug class segment, holding a substantial share due to its effectiveness in managing agitation and pain in ICU patients, alongside increased availability of generic versions supporting market growth.

Key Country Highlights:

• Japan: Increasing demand is supported by a growing elderly population requiring ICU care, coupled with advancements in sedation techniques and healthcare infrastructure.
• United States: Market growth is driven by strong brand presence of leading players like AstraZeneca and GlaxoSmithKline, combined with widespread ICU capacity and innovation in sedative drugs.
• China: The rapidly aging population and rising ICU admissions, along with expanding healthcare infrastructure, contribute significantly to market growth.
• Europe: Increasing elderly ICU admissions and regulatory approvals (e.g., dexmedetomidine centralized EU approval) bolster demand. Europe is also witnessing rising adoption of newer sedatives with better safety profiles such as dexmedetomidine.

Market Segmentation

"Propofol is projected to dominate the global sedation in ICU setting market"

In terms of durgs/drug class, the global market is categorized into propofol, benzodiazepams (midazolam, etc.), dexmedetomidine, remifentanil, and others. Among these, the propofol segment accounted for significant global sedation in ICU setting market share of 46.07% in 2026. Owing to the increasing adoption of propofol in controlling the agitation and pain in mechanical ventilation is anticipated to fuel the growth of the propofol segment in the global market.

Combined with this the recent launch of generic products is also expected to propel the overall sedation in ICU setting market growth. It has been observed that despite many trials comparing sedative regimens, not a single sedative drug is safer and superior to all others. At present, benzodiazepines (such as midazolam), propofol, and dexmedetomidine are the most commonly used sedatives in critical care patients. 

To know how our report can help streamline your business, Speak to Analyst

The new global sedation in ICU setting products, developments and innovations with superior sedation techniques and affordable, safer, potent drugs are considered to be major factors supporting the sedation in the ICU setting market growth in future. 

Regional Analysis

To get more information on the regional analysis of this market, Download Free sample

"Strong Presence of Key Market Players and Higher Cost of Sedatives Enables Market to Hold Considerable Share in Asia Pacific"

Asia Pacific

Asia Pacific generated USD 1.34 billion in global sedation in ICU setting market revenue in 2025 and is expected to dominate the market throughout the forecast period. ICU admissions in the region were estimated at 6,890,471 in 2017 and are projected to increase to 9,273,559 by 2032, driven by rising comorbid illnesses among the aging population and a growing number of critical care beds. Additionally, improving access to advanced intensive care services and increased government investments in healthcare infrastructure are further supporting regional market growth. The number of ICU patients mechanically ventilated and receiving sedatives was estimated at 1,896,051, which is expected to rise to 2,656,108 by 2032, reinforcing sustained demand for sedation therapies.

The Japan sedation in ICU setting market is projected to reach USD 0.23 billion by 2026, the China market is projected to reach USD 0.92 billion by 2026, and the India market is projected to reach USD 0.2 billion by 2026.

Europe

The number of ICU patients mechanically ventilated and receiving sedatives in Europe is anticipated to register a CAGR of 2.4% from 2024 to 2032. Rising ICU admissions of elderly patients suffering from respiratory and infectious diseases, including sepsis, remain a major factor supporting market growth in this region. Moreover, the presence of well-established healthcare systems, standardized ICU sedation protocols, and increasing adoption of short-acting sedatives are contributing to steady demand across European countries. The UK market is projected to reach USD 0.06 billion by 2026, while the Germany market is projected to reach USD 0.31 billion by 2026.

Emerging Regions (North America & Latin America)

Developing healthcare infrastructure, a growing number of hospital ICUs, and rising ICU admissions are major factors supporting the growth of the global sedation in ICU setting market in emerging countries across Asia Pacific and Latin America. Furthermore, expanding private healthcare facilities, increasing availability of trained critical care professionals, and improving awareness regarding optimal ICU sedation management are expected to positively influence market expansion in these regions over the forecast period. The U.S. market is projected to reach USD 1.06 billion by 2026.

Key Market Drivers

"Astra Zeneca, Mylan & GlaxoSmithKline Accounts for More Than Half of the Market Share in Terms of Revenue"

AstraZeneca, GlaxoSmithKline and Mylan are considered to be the top 3 players operating in the market. These three companies have a strong position in global sedation in ICU setting market share in 2024. Established brand presence and strong distribution across the globe are major factors responsible for their strong position in the global market.

There are several generic players operating in the market which cumulatively hold a major share of ICU sedation market. Few of prominent generic players include, Fresenius Kabi, Teva, B. Braun Medical, etc. At present, Propofol considered holding the largest sedation in ICU setting market revenue of around 50% for sedatives used in mechanically ventilated patients in an ICU setting. 

List of Companies Profiled

• Astra Zeneca
• GlaxoSmithKline
• Mylan N.V.
• Fresenius Kabi
• Teva Pharmaceutical Industries
• B. Braun Medical
• Aspen Holdings
• Other prominent players

Report Coverage  

Currently, Benzodiazepines such as Midazolam and Lorazepam considered to be the largest group of drug class holds significant market share in market for sedatives used in mechanically ventilated patients in the ICU settings. Dexmedetomidine is considered to be the fastest growing sedative used in mechanically ventilated ICU patients owing to higher efficiency and comparatively lower adverse effects compared to existing sedatives. 

The report on sedation in ICU setting market provides qualitative and quantitative insights on the sedation in ICU setting industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The sedation in ICU setting market segments include drug/drug class and by region.

In terms of durgs/drug class, the global market is categorized into propofol, benzodiazepines (midazolam, etc.), dexmedetomidine, remifentanil, and others. Geographically, the global market is segmented into four major regions, which are North America, Europe, Asia Pacific, and rest of the World. The regions are further categorized into countries. 

Along with this, the report on global sedation in ICU setting market analysis comprises of the market dynamics and competitive landscape. Various key insights provided in the report are the guidelines for sedation in icu setting – for key countries, technological advancements, pipeline analysis, and advantages & disadvantages of various types of sedation in icu setting by drug class. 

To gain extensive insights into the market, Download for Customization

Key Industry Developments

• In September 2011, the European Commission has granted Dexdor (dexmedetomidine) from Orion, centralized approval covering 27 European Union countries for sedation of adult intensive care unit patients
• In August 2014, Mylan, N.V. launched dexmedetomidine hydrochloride injection, a therapeutically equivalent version of Precedex
• In June 2016, Aspen Holdings signed an agreement with AstraZeneca AB and AstraZeneca to gain exclusive rights to commercialize AstraZeneca’s global (excluding the USA) anesthetic portfolio

Report Scope & Segmentation